再生元制药公司 (REGN) 今日盘中重挫6.78%,引发市场广泛关注。公司盘前股价下跌5.18%,随后跌幅进一步扩大。
根据公司公布的第三季度财报,旗舰眼科药物Eylea新推出的高剂量版本销售额为3.92亿美元,低于分析师预期的4.17亿美元。Eylea是再生元制药公司最重要的收入来源,一直被视为其摇钱树产品。新药销售未达预期引发市场对公司长期增长前景的担忧。
再生元制药公司一直在努力将使用传统Eylea的患者升级至新的高剂量版本,但效果不佳。与此同时,Eylea还面临着包括罗氏的Vabysmo在内的竞争对手激烈竞争,未来可能出现生物仿制药的威胁。竞争日趋白热化,再加上新药销售未达预期,令投资者对该公司长期发展失去信心,从而引发股价大跌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.